|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We classified 166 patients with HER2+ invasive BC into LH (n=110 [66.3%]) and NLH groups (n=56 [33.7%]).
|
31554015 |
2020 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We investigated expression of antigens in breast cancer patients with luminal A (LA), luminal B (LB), HER2 overexpressing (HER2OE), triple negative (TN) subtypes (n=70) and control patients (n=10) without cancer diagnosis.
|
31250425 |
2020 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we presented a heavy pretreated and harbored HER2 V777L mutation de novo stage IV Luminal B (HER2 unamplified) breast cancer patient who achieved an unexpected good response to trastuzumab combined with vinorelbine therapy.
|
31118664 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Luminal B HER2-positive subtype showed the highest expression rate (48.9%).
|
30621641 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
6/82 cases were Luminal A-like (7.3%), 42/82 Luminal B-like (HER2-) (51.2%), 12/82 Luminal B-like (HER2+) (14.6%), 4/82 Non Luminal (HER+) (4.9%), 18/82 Triple Negative (ductal) (22%).
|
30927939 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In subset univariate analyses, the infiltration by MPO-positive cells was associated with significantly better overall survival in the Luminal B/HER2-negative subtype (p = 0.005), the HER2 enriched subtype (p = 0.011), and the Triple Negative subtype (p < 0.001).
|
31267330 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In multivariate analysis, age <50 years, luminal B (HER2 positive) type, HER2 overexpression, and triple-negative subtype were the independent factors to predict a pCR.
|
30987708 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Breast cancer tissues of HER2 overexpression and Basal-like were more significant than Luminal A and Luminal B. MIIP was obviously downregulated and IGFBP2 was upregulated in MDA-MB-231, SKBR3 and MCF-7 versus MCF-10A especially in MDA-MB-231.
|
31078343 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we found PRL pathway gene signature to correlate with favorable patient outcomes in HER-2 and luminal B breast cancer patients.
|
31450192 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Triple-negative breast cancer (TNBC) subtype highly expressed <i>SAA1/2</i> compared to HER2, luminal A (LA) and luminal B (LB) subtypes.
|
30728901 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In BCT cohort, the pooled data showed that there were some significant benefits favoring luminal A over luminal B in LR (OR, 0.61; 95%CI, 0.46-0.81; P = .0007; n = 5406), DM (OR, 0.53; 95%CI, 0.41-0.69; P < .00001; n = 4662), DFS (OR, 0.59; 95%CI, 0.36-0.96; P = .03; n = 776) and OS (OR, 0.65; 95%CI, 0.42-0.99; P = .05; n = 1149), but not in LRR (OR, 0.74; 95%CI, 0.48-1.13; P = .16; n = 3732), coupled with luminal A/B over luminal-HER2 in LRR (OR, 0.43; 95%CI, 0.25-0.76; P = .004; n = 890), DM (OR, 0.56; 95%CI, 0.35-0.90; P = .02; n = 1396), DFS (OR, 0.47; 95%CI, 0.27-0.83; P = .009; n = 532); in mastectomy cohort, there were apparent advantages of LRR (OR, 0.58; 95%CI, 0.36-0.92; P = .02; n = 1768), LR (OR,0.56; 95%CI, 0.38-0.83; P = .004; n = 1209), DM (OR, 0.58; 95%CI, 0.40-0.84; P = .004; n = 652) and OS (OR, 0.62; 95%CI, 0.43-0.89; P = .009; n = 652) in luminal A vs luminal B.
|
30882711 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>in vitro</i> experiment, ectopic expression of FRY could alter the morphology and significantly suppress the growth and proliferation of the breast cancer cell lines, MDA-MB-231 (ER-/PR-/HER2-, Basal-like) and BT474 (ER+/PR+/HER2+, Luminal B).
|
31824855 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most patients with luminal B (86.1%), HER2-enriched (94.4%), and triple-negative (86.8%) breast cancers had abnormal DNA damage response protein expression.
|
30671767 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular classifications of breast cancer (BRC), such as human epidermal growth factor receptor 2 (HER2), luminal A and luminal B, have been developed to reduce unnecessary treatment by dividing patients with BRC into low‑ and high‑risk progression groups.
|
30365075 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The molecular subtypes included: Luminal B/Her-2 negative (n = 89; 40%), triple-negative (n = 69; 32%), Luminal B/Her-2 positive (n = 43; 20%), and Her-2 overexpression (n = 18; 8%).
|
31610321 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The major component was triple-negative cases (69%, 9 of 13) in group 1, luminal B-like (57%, 13 of 23) and HER2-overexpressing (26%, 6 of 23) subtypes in group 2, and luminal A-like subtype (60%, 9 of 15) in group 3.
|
31146704 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Intrinsic subtypes and molecular scores were computed according to published literature and RISK, RS, ROR and EP were compared against each other and to the intrinsic subtypes Luminal A (lumA), Luminal B (lumB), Her2-enriched (Her2↑), Basal-like (basal), and Normal-like (normal) of PAM50.
|
31174485 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The frequency of MLH1 V384D germline mutation in individuals with HER2-positive luminal B BC was significantly higher than that observed in the controls.
|
31358837 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A preoperatively elevated serum ICTP level appears to be an important marker of better prognosis in triple-negative breast cancer and luminal-B-like (HER2-negative) subtypes.
|
31122159 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed 184 (65%) luminal A-like, 57 (20%) luminal B-like/HER2-negative, 17 (6%) luminal B-like/HER2-positive, 6 (2%) HER2-positive/nonluminal, and 18 (7%) triple-negative patients.
|
30694768 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
For each molecular subtype group, Luminal A achieved a sensitivity, positive predictive value, and F1-score of 79.47%, 75.47%, and 77.42%, respectively; Luminal B showed a sensitivity, positive predictive value, and F1-score of 64.58%, 55.86%, and 59.90%, respectively; HER2 had a sensitivity, positive predictive value, and F1-scores of 81.58%, 95.38%, and 87.94%, respectively; BLBC showed sensitivity, positive predictive value, and F1-scores of 62.50%, 89.29%, and 73.53%, respectively.
|
31005170 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ninety five (52.5%) patients experienced axillary downstaging after PST, by molecular subtype 15% (3/20) in Luminal A, 46.4% (45/97) in Luminal B, 90.9% (20/22) in HER2+ and 70.3% (26/37) in triple negative breast tumours.
|
30744944 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Independent risk factors were ADC<sub>1500</sub> entropy (p = 0.002) associated with luminal A, irregular mass shape (p = 0.018) and ADC<sub>1500</sub> entropy (p = 0.022) with luminal B (HER2 positive), mean ADC<sub>1500</sub> (p = 0.018) with HER2 positive, and smooth mass margin (p = 0.012) and rim enhancement (p = 0.003) with triple negative.
|
30116958 |
2019 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SMC harbors higher proportions of HER2+ and Luminal B subtypes, lower proportion of Luminal A with decreased ESR1 expression compared to TCGA.
|
29713003 |
2018 |
|
Luminal B Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients were divided into four groups based on the tumor molecular subtype: luminal A (Estrogen Receptor [ER]/Progesterone Receptor [PR] positive, human epithelial growth factor receptor-2 [HER2] negative), luminal B (ER/PR positive, HER2 Positive), HER2 (HER2 positive and ER/PR negative), and Triple negative (TNBC).
|
30596408 |
2018 |